SPA
CCCC icon

Sherbrooke Park Advisers’s C4 Therapeutics CCCC Stock Holding History

Sherbrooke Park Advisers’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,131
Closed -$62.9K – 848
2023
Q4 		$62.9K Buy
+11,131
New +$25.4K 0.03% 430

Other funds holding CCCC

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Sherbrooke Park Advisers's CCCC Position: Q1 2024 in Review

Sherbrooke Park Advisers sold out of C4 Therapeutics (CCCC) in Q1 2024, closing a stake of 11,131 shares — an estimated $62.9K sold.

Sherbrooke Park Advisers first reported a position in CCCC in Q4 2023 and held it in 1 quarter. The position peaked at $62.9K in Q4 2023. 106 funds tracked by Wall St. Rank hold CCCC as of Q1 2024.

  • Sherbrooke Park Advisers reported no remaining C4 Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 11,131 C4 Therapeutics shares in Q1 2024, an estimated $62.9K.
  • Sherbrooke Park Advisers first reported a position in C4 Therapeutics in Q4 2023 and held it in 1 quarter.
  • Sherbrooke Park Advisers's C4 Therapeutics position peaked at $62.9K in Q4 2023.
  • 106 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2024, filed 15 May 2024.